HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Old Dog, New Tricks: L’Oreal’s Fiscal 2019 Shows Best Growth Since 2007

Executive Summary

L’Oreal is not only learning new tricks in today’s digital world but continuing to outpace the competitive pack, with sales up double digits in fiscal 2019 to €29.9bn.

You may also be interested in...



Dermocosmetics Opportunity Beckons: Top 20 Brands Account For Just 35% Of Global Market – IQVIA

The global dermocosmetics market is led by L’Oréal SA with 13.3% share across 20 countries evaluated, followed by Pierre Fabre Group with 7.4%. According to IQVIA Consumer Health, this points to a fragmented market with ample room for innovative, “nimble” brands to enter and nab share.

L’Oreal Q2 Lifted By Consumer Biz Revival And ‘Probably Our Greatest Makeup Launch Ever’

Maybelline Lash Sensational Sky High Mascara, along with NYX Shine Loud Lip Color and L’Oreal Paris Infallible Fresh Wear 24HR Foundation, were among innovations gobbled up by makeup-hungry consumers in the second quarter, which helped fuel 23% growth in North America in L'Oreal's fiscal 2021 first half.

L’Oreal Optimistic About Post-Shutdown Growth, Notes Likely Thinning Of Beauty Field

“It's unfortunate, but it's the Darwinian side of this industry,” L’Oreal CEO Jean-Paul Agon said on 16 April while discussing newer players’ prospects for survival through the COVID-19 crisis and L’Oreal’s own first-quarter results – down 4.8% like-for-like, but ahead of the market.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS149692

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel